The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.
 
Khalid Jazieh
No Relationships to Disclose
 
Mohammadhadi Khorrami
No Relationships to Disclose
 
Anas M. Saad
No Relationships to Disclose
 
Mohamed M. Gad
No Relationships to Disclose
 
Vidya Sankar Viswanathan
No Relationships to Disclose
 
Pingfu Fu
No Relationships to Disclose
 
Prabhakar Rajiah
No Relationships to Disclose
 
Anant Madabhushi
Leadership - Inspirata
Stock and Other Ownership Interests - Elucid Bioimaging; Inspirata
Honoraria - AstraZeneca; Inspirata
Consulting or Advisory Role - Aiforia; Merck
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers-Squibb (Inst); Inspirata (Inst); Philips Healthcare (Inst)
Patents, Royalties, Other Intellectual Property - IP Licensed by Elucid Bioimaging (Inst); IP licensed by Inspirata Inc. (Inst)
 
Nathan A. Pennell
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cota Healthcare; G1 Therapeutics; Genentech; Inivata; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Viosera Therapeutics; Xencor
Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Heat Biologics (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); WindMIL (Inst)